ANIK logo

Anika Therapeutics Inc. (ANIK)

$12.92

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ANIK

Market cap

$173067444

EPS

-0.13

P/E ratio

--

Price to sales

2.17

Dividend yield

--

Beta

0.213538

Price on ANIK

Previous close

$13.40

Today's open

$13.58

Day's range

$12.84 - $13.58

52 week range

$9.01 - $22.88

Profile about ANIK

CEO

Stephen Griffin

Employees

235

Headquarters

Bedford, MA

Exchange

Nasdaq Global Select

Shares outstanding

13395313

Issue type

Common Stock

ANIK industries and sectors

Healthcare

Medical Equipment & Supplies

News on ANIK

What Anika Therapeutics (ANIK) Said on Its Q3 Earnings Call

Anika Therapeutics NASDAQ: ANIK reported a 10% increase in third-quarter revenue and raised the lower end of its 2026 revenue and adjusted EBITDA margin forecasts, even as it lowered its commercial channel growth outlook following slower U.S. elective surgery activity.

news source

MarketBeat • Nov 6, 2026

news preview

Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript

Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 6, 2026

news preview

Anika Reports Third Quarter 2026 Financial Results

Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in IntegrityTM Revenue Secured New 10-Year Hyvisc® Partnership with Enhanced Economics; Reintroduced Hyaff Non-Orthopedic OEM Product Raised Lower End of Full-Year 2026 Total Company Revenue Guidance and Raised 2026 Adjusted EBITDA Guidance BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), the global leader in the design, development, manufacturing and commercialization of hyaluronic acid (HA) innovations, today announced financial results for the third quarter of 2026.

news source

GlobeNewsWire • Nov 6, 2026

news preview

Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates

Anika Therapeutics (ANIK) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.04 per share a year ago.

news source

Zacks Investment Research • Nov 6, 2026

news preview

Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026

BEDFORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2026 financial results before the opening of the market on Friday, November 6, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.

news source

GlobeNewsWire • Oct 22, 2026

news preview

Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?

Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.

news source

Zacks Investment Research • Sep 25, 2026

news preview

Best Momentum Stocks to Buy for August 26th

BTSG, ANIK and OPHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 26th, 2026.

news source

Zacks Investment Research • Aug 26, 2026

news preview

Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why

Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

news source

Zacks Investment Research • Aug 24, 2026

news preview

Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?

ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.

news source

Zacks Investment Research • Aug 21, 2026

news preview

5 Stocks With Recent Price Strength to Enhance Your Portfolio Returns

Five stocks, including EDRY, OPHC, FET, ANIK and NESR, show strong recent price gains and earnings growth as markets rally.

news source

Zacks Investment Research • Aug 19, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Anika Therapeutics Inc.

Open an M1 investment account to buy and sell Anika Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ANIK on M1